Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Body mass index as a predictor of fracture risk: A meta-analysis
20051.2k citationsAnders Odén, J. A. Eisman et al.Osteoporosis Internationalprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of J. A. Eisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Eisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Eisman more than expected).
This network shows the impact of papers produced by J. A. Eisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Eisman. The network helps show where J. A. Eisman may publish in the future.
Co-authorship network of co-authors of J. A. Eisman
This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Eisman.
A scholar is included among the top collaborators of J. A. Eisman based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with J. A. Eisman. J. A. Eisman is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Papapoulos, Socrates E., DW Dempster, J. A. Eisman, et al.. (2013). Phase 3 Fracture Trial Of Odanacatib For Osteoporosis - Baseline Characteristics and Study Design. Osteoporosis International. 24.3 indexed citations
Dempster, David W., J. A. Eisman, S. L. Greenspan, et al.. (2010). Phase 3 Fracture Trial of Odanacatib for Osteoporosis - Study Design. Endocrine Reviews. 31(3).1 indexed citations
Johnell, O., JA Kanis, H Johansson, et al.. (2006). Prior clinical vertebral fractures are a particularly strong predictor of hip fracture: A meta-analysis. Osteoporosis International. 17.3 indexed citations
10.
Diamond, Terrence, J. A. Eisman, Rebecca S. Mason, et al.. (2005). Reply to : Vitamin D and adult bone health in Australia and New Zealand: a position statement.. The Medical Journal of Australia. 183(1). 52–53.1 indexed citations
11.
Seeman, Ego & J. A. Eisman. (2004). MJA Practice Essentials. 7: Endocrinology - Treatment of osteoporosis: why, whom, when and how to treat. The Medical Journal of Australia. 180(6).1 indexed citations
Jones, Graeme, Thanh Van Nguyen, Philip N. Sambrook, et al.. (1995). Osteoarthritis, bone density, postural stability, and osteoporotic fractures: a population based study.. PubMed. 22(5). 921–5.120 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.